Spyre Therapeutics Inc SYRE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026
-
Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
-
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
-
Spyre Therapeutics Announces Grants of Inducement Awards
-
Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations
-
Spyre Therapeutics Announces Grants of Inducement Awards
-
Spyre Therapeutics to Participate in Upcoming September Investor Conferences
-
Stocks to Watch: Intuit, Spyre Therapeutics, Zoom Communications, nCino
Trading Information
- Previous Close Price
- $95.51
- Day Range
- $96.51–100.00
- 52-Week Range
- $21.15–110.18
- Bid/Ask
- $89.00 / $97.00
- Shares Outstanding
- 94.97M
- Market Cap
- $9.28B
- Volume/Avg
- 904,899 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 112
- Website
- https://www.spyre.com
Valuation
|
Metric
|
SYRE
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 9.80 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
SYRE
Financial Strength
|
Metric
|
SYRE
|
|---|---|
Quick Ratio | 26.70 |
Current Ratio | 27.40 |
Interest Coverage | — |
Quick Ratio
SYRE
Profitability
|
Metric
|
SYRE
|
|---|---|
Return on Assets (Normalized) | −32.83% |
Return on Equity (Normalized) | −43.85% |
Return on Invested Capital (Normalized) | −39.86% |
Return on Assets
SYRE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|??p>@D | LOCK|&<MY | $135B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|wGQzzj! | LOCK|dW#<X | $101B | |||
| Moderna Inc
MRNA
| LOCK|^&#?k?y | LOCK|@q | $91B | |||
| argenx SE ADR
ARGX
| LOCK|v?!c@< | LOCK|&y | $56B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|%^rK#l | LOCK|DN | $41B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|!spf!tNh | LOCK|?FyrP | $30B | |||
| Incyte Corp
INCY
| LOCK|jw^>Wg | LOCK|$Rz | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|$#yD&z | LOCK|TWk | $22B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|N>%Z%D | LOCK|!jxg | $21B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|@!#<&Gd | LOCK|$C | $15B |
United States